Shire recently set up a $5 billion credit facility from multiple banks led by Citigroup (C) to finance its takeover offer for NPS. The Financial Times reported that NPS board member Colin Broom would play a crucial role in the takeover conversations. Broom also serves as the chief scientific officer of ViroPharma, which Shire acquired last year.
NPS' only approved product in the U.S. and Europe is Gattex/Revestive, a treatment for adult PN-dependent short bowel syndrome.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was up 13.81% to $35.43 at 10:15 a.m. on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts